• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    iECURE Enters Agreement with Center for Breakthrough Medicines

    CPDC Enters Clinical Manufacturing Deal with CellBion

    Olon to Build New R&D Center in Italy

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    CRO Market Insights

    Hanmi Fine Chemical Launches CDMO Business

    DFE Pharma Opens India CoE for Fast-Track Formulation Services

    Helsinn Establishes New R&D Hub in the U.S.

    CureVac, myNEO Partner on Antigen Targets for mRNA-Cancer Vax Development
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Vector Partners Limited

    IDT Biologika

    CMC Pharmaceuticals

    Qosina
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Vector Partners Limited

    IDT Biologika

    CMC Pharmaceuticals

    Qosina
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    02 Roche

    ...

    Related CONTENT
    • Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    • U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail
    • Novo Nordisk Launches Foundation Center for Genomic Mechanisms of Disease
    • Adaptimmune, Genentech Enter Strategic R&D Collaboration
    • Thermo Fisher, AstraZeneca Collaborate on NGS-Based Companion Diagnostics
    07.20.18
    Headquarters: Basel, Switzerland
    twitter.com/Roche
    www.roche.com

    Headcount: 93,734 
    Year Established: 1896
    Total Revenues: $54,591  (+5%)
    Pharma Revenues: $42,219  (+5%)
    Net Income: $9,039  (-9%)
    R&D: $11,566  (+2%)

    TOP SELLING DRUGS  
    Drug Indication 2017 Sales (+/-%)
    MabThera/Rituxan cancer, rheumatoid $7,506 1%
    Herceptin arthritis $7,506 1%
    Avastin breast cancer $6,794 2%
    Perjeta breast cancer $2,231 23%
    Actemra/RoActemra rheumatoid arthritis $1,957 18%
    Xolair asthma $1,770 20%
    Lucentis macular degeneraton $1,436 4%
    Activase/TNKase acute myocardial infarction $1,238 14%
    Kadcyla breast cancer $928 14%
    Esbriet pulmonary fibrosis $883 13%
    Tarceva lung cancer $856 -14%
           

    Roche Group’s pharmaceutical business reported solid overall results in 2017. Revenue grew 5% to $42.2 billion from $38.3 billion a year ago—good enough to move into the number two spot from four last year.

    Pharmaceutical sales growth contributed $1.4 billion of new sales, representing 65% of the division’s growth. In oncology, HER2 franchise sales increased by 7% to $10.1 billion, led by Perjeta. MabThera/Rituxan sales were $7.5 billion, a growth of 1% globally, despite sales in Europe being 11% lower following biosimilar entry. Sales of Avastin were $6.7 billion, a decline of 2% due to competitive pressure. Sales in immunology grew to $7.6 billion, with Xolair and Actemra/RoActemra increasing by 16% and 14% respectively. Sales of Tamiflu fell by 33% due to competition from generics in the U.S. market.

    During the year, the Swiss drug maker scored a major victory when FDA approved Ocrevus, a new multiple sclerosis (MS) drug from Roche’s Genentech unit that is poised to make a major impact on the market for MS and could prove to be a blockbuster. Since its launch, more than 30,000 prescriptions have been written and sales estimates for 2022 are projected to be more than $4 billion.

    To say the FDA’s approval of the drug back in March 2017 was big news in the MS world is an understatement. Why is Ocrevus touted for being the leading new drug approval from the class of 2017? Well, there are approximately 15 other medications—known as disease-modifying treatments, or DMTs — for MS, but they only treat the most common form of MS, called relapsing-remitting multiple sclerosis (RRMS).

    Ocrevus is groundbreaking because, while it has been very effective for RRMS, it is also the first medication approved to treat primary-progressive multiple sclerosis (PPMS), a less-common form of the disease. According to the National Multiple Sclerosis Society, 85 percent of people with MS have RRMS, while 10 to 15 percent are diagnosed with PPMS.

    Roche was awarded several other new drug approvals during the year, some of which are highlighted here. First, FDA gave the green light to cancer drug Perjeta, in combination with Herceptin and chemotherapy—the Perjeta-based regimen—for adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence.

    The drug enforcer also approved Roche’s Gazyva for previously untreated advanced follicular lymphoma. The approval marks the first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy.

    Hemlibra for haemophilia A with inhibitors was approved and is the first new medicine in nearly 20 years to treat people with haemophilia A with inhibitors. The drug was shown to substantially reduced bleeds in adults and children.

    FDA also approved Zelboraf for Erdheim-Chester disease with BRAF V600 mutation. Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease (ECD), a rare blood disease.
    Alecensa also was approved as a first-line treatment for people with specific type of lung cancer. Approval was based on Phase III results that showed Alecensa extended the average time that people lived without their disease worsening compared to crizotinib.

    Actemra/RoActemra was approved for the treatment of CAR T cell-induced cytokine release syndrome. Actemra/RoActemra is the first FDA-approved treatment for severe or life-threatening cytokine release syndrome induced by CAR T cell therapy. This marks the seventh FDA approval for Actemra/RoActemra since its U.S. launch in 2010
    Lasty, FDA ok’d Roche’s Lucentis for diabetic retinopathy, the leading cause of blindness among working age adults in the U.S. It is the first and only medicine approved to treat all forms of diabetic retinopathy on the market.

    Billion dollar deals
    At the start of 2018 Roche made a couple of major M&A transactions. First, to boost its cancer pipeline, it paid $1.7 billion to acquire Ignyta, Inc., a U.S. based pharmaceutical company focused on developing cancer therapies. The acquisition expands Roche’s oncology portfolio globally. Ignyta is responsible for the ongoing study of entrectinib, its most advanced cancer drug being studied in a range of solid tumor types. The company also has a portfolio of drugs in early stage development that use gene therapy to kill the underlying diseases that drive cancer tumor growth. Ignyta employs an integrated “Rx/Dx” approach that combines precision medicines (Rx) and in-house molecular diagnostics (Dx) to both identify and target hard-to-treat cancers in hard-to-find patients.

    Second, Roche continued its push into the personalized healthcare space with the purchase of Flatiron Health in a deal worth $1.9 billion. Flatiron is a healthcare technology and services company focused on accelerating cancer research and improving patient care. They develop oncology-specific electronic health record (EHR) systems, most notably an information exchange platform which allows researchers to access and learn from patient records. The company’s message is that large amounts of data could be used to speed up and, in some cases, replace certain clinical trials where patients are randomly assigned to a specific treatment.

    Roche’s chief executive of its pharma division, Dan O’Day said the deal marks an important step in its personalized healthcare strategy for Roche. “We believe that regulatory-grade real-world evidence is a key ingredient to accelerate the development of, and access to, new cancer treatments,” he said. “As a leading technology company in oncology, Flatiron Health is best positioned to provide the technology and data analytics infrastructure needed not only for Roche but for oncology research and development efforts across the entire industry.” Previously, Roche led a Series C funding round for Flatiron in 2016.

    In other precision medicine news, during the year Syapse and Roche entered into a multi-year strategic collaboration to help make precision medicine available to more cancer patients. The two companies unveiled plans to work jointly to develop software products and analytics solutions to provide the tools and insights healthcare providers need to practice precision medicine at scale, with the goal of improving patient outcomes. Roche is funding the development of these products, which aim to benefit oncologists, health systems, and stakeholders including payers. Syapse will develop and deploy these new products to the precision medicine ecosystem, beginning with its existing healthcare provider network.

    The companies will initially focus on four product programs: real-world evidence, so that physicians can make better care decisions; better understanding the health economics impact and patient outcomes of precision medicine; advancing electronic patient-reported outcomes to understand precision medicine’s effect on health-related quality of life; and accelerating clinical trial enrollment by matching patients to precision trials at the point of care. Roche and Syapse will also collaborate on automated methods for measuring real-world outcomes.

    Research Collaborations
    On the collaboration front, during the year Roche teamed up with Confo Therapeutics for the discovery, development and commercialization of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders. Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialization. The financial terms included an upfront payment, preclinical milestones and research funding to Confo Therapeutics totaling more than $7 million over the first 30 month period with up to $96.3 million in milestone payments.

    Roche’s Genentech unit was also very active in research tie-ups. At the very end of 2016 Genentech extended its exclusivity period for the research collaboration and license agreement with Phylogica Ltd. to discover novel antibiotics using Phylogica’s Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.

    At the beginning of 2017 Corvus Pharmaceuticals expanded its clinical collaboration with Genentech for CPI-444 in combination with atezolizumab (Tecentriq) to be evaluated in a Phase Ib/II clinical study as second-line therapy in non-small cell lung cancer (NSCLC). The study will be part of Morpheus, Genentech’s novel cancer immunotherapy platform established to develop immunotherapy combination therapies more rapidly and efficiently. CPI-444, Corvus’ lead product, is a selective and potent inhibitor of the adenosine A2A receptor. Atezolizumab, developed by Genentech, is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1).

    With Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, Genentech expanded an existing license agreement for the development of new therapeutics using Arvinas’ Protac technology. The multi-year strategic collaboration initiated in October 2015 will now encompass additional disease targets. The Protac platform removes target proteins directly rather than inhibiting them. This differs from small molecule inhibitors, which often result in toxic side effects and eventual drug resistance. Under the revised terms of the agreement, Arvinas is now eligible to receive development and commercialization milestone payments in excess of $650 million. In addition, they are also able to receive tiered-royalties on sales of products resulting from the license agreement.

    Genentech and Biothera Pharmaceuticals entered into a clinical trial collaboration agreement to assess the safety and efficacy of Biothera’s Imprime PGG in combination with Genentech’s atezolizumab, an anti-PD-L1 antibody, and bevacizumab, an anti-VEGF antibody, to treat patients with metastatic colorectal cancer. Genentech will conduct the multicenter trial, which will enroll approximately 40 patients in the initial phase of the study. Under the agreement, researchers will evaluate the potential of Imprime PGG, atezolizumab and bevacizumab to increase overall patient responses.

    At the start of 2018, Genentech and Syndax Pharmaceuticals formed a new clinical collaboration to evaluate the combination of Syndax’s entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech’s programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (Tecentriq), in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic breast cancer. The planned Phase Ib/II, open-label, multicenter, randomized trial will enroll patients with metastatic HR+, HER2- breast cancer who have experienced disease progression during or following first-line therapy. Genentech will be responsible for conducting the trial. 
    Related Searches
    • it
    • analytics
    • data analytics
    • combination therapies
    Suggested For You
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail
    Novo Nordisk Launches Foundation Center for Genomic Mechanisms of Disease Novo Nordisk Launches Foundation Center for Genomic Mechanisms of Disease
    Adaptimmune, Genentech Enter Strategic R&D Collaboration Adaptimmune, Genentech Enter Strategic R&D Collaboration
    Thermo Fisher, AstraZeneca Collaborate on NGS-Based Companion Diagnostics Thermo Fisher, AstraZeneca Collaborate on NGS-Based Companion Diagnostics
    Roche, Shape Therapeutics Enter Strategic Gene Therapy Collaboration Roche, Shape Therapeutics Enter Strategic Gene Therapy Collaboration
    Ensuring Equitable Access to Next-generation Sequencing in Oncology Ensuring Equitable Access to Next-generation Sequencing in Oncology
    AltheaDx Expands Commercial Leadership Team AltheaDx Expands Commercial Leadership Team
    Japan First to Approve Roche’s Ronapreve to Treat COVID-19 Japan First to Approve Roche’s Ronapreve to Treat COVID-19
    Biogen Biogen
    Sequanta, Mission Bio Enter Strategic Pact Sequanta, Mission Bio Enter Strategic Pact
    Mimetas, Roche to Develop Human Disease Models for Drug Development Mimetas, Roche to Develop Human Disease Models for Drug Development
    Coriolis Pharma Coriolis Pharma
    Roche’s Actemra Receives FDA EUA to Treat COVID-19 Roche’s Actemra Receives FDA EUA to Treat COVID-19
    Biovectra Inc. Unveils New Logo and Brand Biovectra Inc. Unveils New Logo and Brand

    Related Content

    • Biologics, Proteins, Vaccines | Breaking News | Clinical Trials
      Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany

      Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany

      Covers the combination of DHODH inhibitors and nucleoside analogues to treat viral infections, including Covid-19.
      09.22.21

    • Breaking News | Industry News
      U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail

      U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail

      Will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022.
      09.15.21

    • Breaking News | Drug Development | Drug Discovery | Industry News | Information Technology
      Novo Nordisk Launches Foundation Center for Genomic Mechanisms of Disease

      Novo Nordisk Launches Foundation Center for Genomic Mechanisms of Disease

      Initiative, together with the Broad Institute of MIT and Harvard, aims to accelerate efforts to mine genetic data for insights into disease mechanisms.
      09.15.21


    • Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery
      Adaptimmune, Genentech Enter Strategic R&D Collaboration

      Adaptimmune, Genentech Enter Strategic R&D Collaboration

      To research, develop, and commercialize cancer-targeted Allogeneic T-cell therapies.
      09.07.21

    • Breaking News | Collaborations & Alliances
      Thermo Fisher, AstraZeneca Collaborate on NGS-Based Companion Diagnostics

      Thermo Fisher, AstraZeneca Collaborate on NGS-Based Companion Diagnostics

      Aim to accelerate development and introduction of targeted precision medicine therapies for patients.
      09.02.21

      Trending
      • Catalyst Biosciences Sells Complement Portfolio To Vertex Pharmaceuticals | Contract Pharma
      • Hanmi Fine Chemical Launches CDMO Business | Contract Pharma
      • CureVac, MyNEO Partner On Antigen Targets For MRNA-Cancer Vax Development | Contract Pharma
      • Mirum Pharmaceuticals Acquires San Diego-based Satiogen | Contract Pharma
      • Insmed Appoints Drayton Wise As Chief Commercial Officer | Contract Pharma
      Breaking News
      • iECURE Enters Agreement with Center for Breakthrough Medicines
      • CPDC Enters Clinical Manufacturing Deal with CellBion
      • Olon to Build New R&D Center in Italy
      • Hanmi Fine Chemical Launches CDMO Business
      • DFE Pharma Opens India CoE for Fast-Track Formulation Services
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Alkemist Labs Announces Alkemist Assured Seal and Next Generation Transparency Reports
      GC Rieber Foundations Expand Philanthropic Efforts
      Coatings World

      Latest Breaking News From Coatings World

      Nippon Paint Automotive Americas Appoints Robert Angart CEO and President
      Sustainability, Economy are Focus of BCF’s Annual Conference
      Demand for Rhino Shield Increases
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 28
      New Breast Implant Surgery Guidelines to Enhance Patient Safety
      Rhythm Management Group Debuts RhythmSynergy Tech Platform
      Contract Pharma

      Latest Breaking News From Contract Pharma

      iECURE Enters Agreement with Center for Breakthrough Medicines
      CPDC Enters Clinical Manufacturing Deal with CellBion
      Olon to Build New R&D Center in Italy
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      K-Beauty Brand Siita Shares Plastic Decomposition Technology with the Beauty Industry
      Shellworks Raises $6.2 Million in Seed Funding
      Ulta Beauty Reports Record First Quarter 2022 Results
      Happi

      Latest Breaking News From Happi

      Honeywell Addresses Critical Issues Such as Sustainability, Workforce Training and Digitalization
      Monat Global Wins Four Stevie Awards in the 20th Annual American Business Awards
      Coty Expands Vegan Beauty Portfolio With New Rimmel Mascara
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Flint Group, New Inks from Siegwerk and Zeller+Gmelin Lead This Week’s News
      Orion to Finish Gas Black Expansion in Germany by Early 2023
      Richard Childress Racing Shows Off New Wraps for 2022 NASCAR Season
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      UPM Raflatac accelerates label growth with acquisition
      Labelexpo Asia 2022 postponed
      Teklynx software helps Top Clean Injection validate labels
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Rael Raises $35M in Series B Funding
      Schobertechnologies Offers Rotary Web-fed Converting Solutions
      Thorne Relaunches Gut Health Test with Microbiome Wipe
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most-Read Stories This Week—May 28
      Toetal Solutions Raises $1.02 Million in New Financing
      ManaMed's ManaSport Wearable Ultrasound Earns FDA Nod
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: OPV’s Future, Graphene Flagship and Japan Display Top This Week’s Stories
      SEMI Foundation Receives $1.5 Million Grant to Bolster Michigan’s Semiconductor Talent Pipeline
      onsemi Recognized by Fortune 500 for Its Transformation Journey

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login